Open access
CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia.
M. Shadman
M. Redman
Sang-Yun Lee
K. Baker
Dong-Hoon Lee
Da-Chun Qian
Cecilia C. S. Yeung
B. Dezube
Manuel Litchman
C. Till
Xiao-Ling Song
F. Otegbeye
A. Chapuis
R. Cassaday
E. Warren
Filippo Milano
J. Gauthier
A. Hirayama
Mary L. Kwok
L. Iovino
C. Ujjani
D. Maloney
Ajay K. Gopal
B. Till
Medicine
Abstract
No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729.